Sharing influence of biofilm & developing CAPRISE cleansing systems.

Review multi-disciplinary viral genomic research identifying mutagens through biofilm profiling, creating open-source pathogenic databases. 

Develop CAPRISE systems using quantum sensors and plasma technology for indoor and transport pathogen cleansing. 

Engage with LMIC agencies/NGOs providing educational, indigenous source information, assess outbreak/spill-over risk factors using AI, and establish a multi-disciplinary PRO-ACT team.

Dr Walter Battistutti

The cause of viruses being transmitted through touch is found in biofilm colonies formed from a combination of organisms that adhere to surfaces (see Section 24 for a short video on biofilm). ‘Biofilm infections are estimated to be responsible for up to 80% of all infections in humans and animals, posing a major health challenge’ (Microbiology Society, 2019).

Core problems that we will address include the identification of viral biofilm structures; what organisms combine to form them; analysis of indigenous mutagens enabling viral mutations and how to deactivate/eradicate them.

As the Covid-19 pandemic has shown, the scale is unprecedented, affecting economies and millions of lives. With biodiversity being adversely affected by man’s ‘progress’, influencing the evolution of increasingly virulent viruses (mainly zoonotic), further outbreaks are a real threat. 

Considerable, purely academic, genomic, and proteomic research across many disciplines is not coordinated, publically shared, or applied to inform, solve viral causality or transmission issues.

No safe or compact, integrated system for effectively cleansing biofilm exists. Infected surfaces do not show up from swab testing and travel turns epidemics into pandemics.

The influence and devastating effect of biofilm transmission needs to be addressed for all infectious diseases.

The target audiences are several including:

The Academic World and Professionals in the Field providing a platform of current research and show findings and a moderated article upload facility with a discussion and Q&A forum. This will connect, share expertise, challenge with considered appeals and encourage an applied approach. Academics need to be more engaged with providing practical as opposed to theoretical solutions.

High-risk LMIC Communities through the identification of indigenous pathogens and mutagens, especially of zoonotic origin that affect many peoples. This will enable sources of infection to be identified and where vector breeding grounds are leading to either eradication and the creation of health education programs to be implemented.

Government Public Health and Policy Makers to be informed of potential outbreaks and to provide impartial protocols and action plans by the PRO-ACT team neutralising misinformation, political gain, and vested interests.

Health Services to offer the sharing of data from both disease analytics as well as from patients

The Business Community in providing the CAPRISE solution to reduce risk of infection and subsequent sickness levels.               

Progress of the solution and different aspects will be continually updated on all major social media platforms with open online seminars and discussion groups.

Analysis of all genomic research, enhanced by biofilm profiling data, our solution will provide the knowledge to identify the origins, sources, biological equations, and conditions that give rise to virulent viruses. All this information will be accessible in an open-source platform together with the interactive capability to provide the tools for public health to plan, educate the public and assist local professionals in understanding indigenous factors and act accordingly.

The PRO-ACT team will focus on providing the most informed action plans on serious outbreaks, regardless of location, and create a program to develop non-profit genetically safe vaccines to distribute where needed on fair, non-discriminatory terms.

We also intend to use the profit from corporate sales of CAPRISE to establish co-ordination centres in areas of high risk, develop compact, integrated systems for transport vehicles, and provide them as non-profit units to LMIC governments, NGO’s and charities to enable adaptation of existing transport vehicles for the public good.

Public good would also be at the heart of further research into man’s effect on biodiversity through deforestation, habitat destruction, global warming, and weakening of the human immune system mainly through food preparation with subsequent loss of genetic markers.

In the short term, our solution will assist in the current Covid-19 pandemic through initial interdisciplinary research analysis/biofilm profiling and production of CAPRISE for indoor spaces, safely eradicating resilient viral biofilm, preventing static transmission in home, work, and communal areas.

This pilot will set benchmark parameters for identifying active components that cause existing disease and potential threats. Clear visual health education will explain the causes, identify likely sources and provide logical precautionary and environmental advice to populations in vulnerable areas. Although knowledge is power, local professionals will have the support and tools to identify indigenous threats and share findings for the global community to assess the most appropriate action to counter existing and future threats.  

Further development of integrated CAPRISE systems will minimise the spread of many infectious diseases, especially through international travel.

The interactive cloud reporting function will be expounded to include a daily mandatory symptom reporting function (to be negotiated) for primary care and hospitals with AI analysis generating risk assessment reports.

Ultimately, our research will provide data to enable the creation of genetically safe pure proteinaceous viral vaccines free from nucleic acids. Research has found that hereditary defects in man can be caused by attenuated viral vaccines.

Once data from GISAID and other genomic research is analysed, academic institutions with laboratory facilities in the NBIC network, combined with a post-doc program funding aligned research will enable a scalable program to be carried out to populate the known viral threat database in the first year.

Within this timescale, the plasma system will be developed with Terraplasma and mounted onto our existing module. Algorithms will be written and tested with the sensor array ready to target a pilot cleansing program. 

Manufacturing capabilities have been agreed upon, but further options are being explored for component parts to be made in China and assembled in the UK.

Initially, UK contracts will be negotiated to be used in 9250 GP practices. A franchise network will enable the roll-out of CAPRISE over the next 3 years. 

The data flow will be shared with NGOs on the ground enabling threats to be calculated and health education programs put into place.

In situ programs will be set up to target specific viral threats in a rolling program concurrent with the development of compact integrated plasma systems for transport. The aim is to control identified virus transmission and prevent epidemics from becoming pandemics.

Within the research and analysis framework we will monitor the artificial biofilm environment to divide snapshots into very small frozen subunits designed to measure using systematic methods, aperiodic change in the biofilm and their ‘residents’ within the virulent colonies (bacteria, richettsiae, viruses, mycotic disease pathogens etc).

We intend to establish native indicators aligned to biofilm profiling parameters in order to measure changes observed in sampling done by professionals at sources of identified and potential outbreaks. 

Where the specific infectious disease has been profiled and indigenous organisms identified and a program implemented to locate the source and educate the population, then both local NGO data on global surveillance will be compared over a period of time.

Where CAPRISE is used, the sensors will provide data of pathogen type and concentration before and after cleansing. Similarly, cultures taken from risk area samples will be compared to past data and time-stamped to give a graphic indication of change over time.

Financial - this is the main issue. Clearly, a considerable amount of investment is needed to implement the integrated program we have been working on for a year. If unsuccessful with the Trinity Challenge as our ideal partners, we would have to split the project and spend the next year applying for grants, if the company can survive.

Technical - we believe that all aspects have been covered.

Legal - obviously there will be legal issues, but through partner collaborations, these should be able to be resolved.

Cultural - providing health education is difficult for many reasons and we would consult with NGO partners.

Governments - similar to cultural, however, our intended partnership with Brunswick we believe that regulatory and policy issues can be addressed successfully.

Market and scalability - the potential of CAPRISE in addressing global issues of disease transmission through innovative new technology is enormous, so there might be problems of manufacturing capacity as demand once contracts are agreed will be urgent by nature. We have already started to identify component part manufacturing in China for assembly in the UK to address this issue.

Organisational - dealing across the world always creates barriers, we just have to persevere.

UK

• NBIC – National Biofilm Innovation Centre
• University of Essex
• University of Worcester
• University of Birmingham
• Cambridge Infectious Disease Centre
• Hospital for Tropical Diseases
• Axis PEC Ltd
• Swifter Ltd
• MediHub Ltd

Germany

• Terraplasma Medical/Max Planck Institute

Israel

• Prospec - Tany TechnoGene Ltd

Singapore

• Centre for Environmental Life Sciences Engineering

USA

• Institute of Genomic Medicine

Global 

• EcoHealth Alliance

The ethos of the Trinity Challenge perfectly aligns with our own. We use applied research to develop innovative concepts and are developing strong and like-minded collaborations in specialist areas and have started to plan for a ‘next generation of plasma cleansing for indoor spaces using bespoke algorithms applied to research data in order to identify and negate threats but the pandemic prevented us from generating funds to progress. Trinity Challenge offers funded opportunities to open doors and attain goals.

The human race has a tendency to be complacent and it is only when disaster strikes that serious action is taken. This pandemic has acted as a catalyst for the Trinity Challenge to change thinking for the long term, break down barriers and engender collaboration across all sectors. The Trinity Challenge provides the fresh altruistic impetus to stir up academia, corporate and political vested interests, the latency of potential and litigious paranoia preventing openness.

Protlab has the expertise to connect, analyse and enhance relevant research, to resource manage through collaborations and vision to implement data-driven applications and analytics to identify threats and respond to man’s detrimental influence on disease transmission. We can only achieve this with influential support and funding.

To attain optimum success, proposed Trinity Challenge Member partnerships/collaborations are:

• Global Virome Project – to share our aims, methods, and vision and to collaborate on a high level.
• Google – to help propagate PHIL database (see section 12), using search scripts to identify specialties, sub-specialties, and interests, which automatically generate web content. PHIL is a knowledge-based service to engage doctors globally supporting those doctors in areas of high-risk outbreaks, generally LMICs. Doctors have a ‘need’ to attain the highest of standards and be informed.
• Patrick J McGovern or Blue Dot – to integrate the data system and flow
• The Brunswick Group to engage with political and social stakeholders as well as liaise on regulatory issues.

However, many founders and members have relevance to our project and know in much more detail where we have synergy, so a reverse collaborative selection process would be more appropriate. We would very much like to work with the Bill & Melinda Gates Foundation as they encompass the integrated nature of our project, however, they appear to be limited to US companies only.

Other relevant collaborations would be established as the project evolves and positive opportunities and applications are identified.